PolyPeptide Reports Growth and Profitability Enhancements in 2025

PolyPeptide Group AG, a prominent CDMO for peptide-based active pharmaceutical ingredients, announced robust financial results for 2025. The company reported a revenue increase of 15.6% to EUR 389.3 million, with constant currency growth slightly higher at 16.0%. The EBITDA rose noticeably to EUR 46.8 million, marking an 84.4% increase, attributed to improved operational performance and higher production volumes.

The revenue benefited from a 29.9% increase in development and a 7.9% rise in commercial revenue. The significant customer demand led to substantial investments across global manufacturing sites, with capital expenditures reaching EUR 110.0 million.

Looking ahead, PolyPeptide aims for 20-25% revenue growth in 2026, with continued enhancements in EBITDA margins and capital expenditures aligned with mid-term targets. The strategic expansion efforts encompass geographical diversity and advanced manufacturing capabilities, positioning the company for future successes.